Co-Diagnostics
Co-Diagnostics (NASDAQ: CODX) is a Salt Lake City-based molecular diagnostics company that develops proprietary Co-Primers-based real-time PCR instruments (Co-Dx PCR Pro, PCR Home, and Co-Dx Box) and multiplex test kits for infectious diseases, serving clinical laboratories, healthcare facilities, governments, and at-home consumers across 50+ countries via direct sales, joint ventures, and distributors.
- Company typePublic
- Founded2013
- HeadquartersSalt Lake City, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Co-Diagnostics does
Co-Diagnostics, Inc. (NASDAQ: CODX) is a Utah-based molecular diagnostics company founded in 2013 that develops proprietary real-time PCR instruments and multiplex test kits built around its Co-Primers technology, which improves specificity and reduces primer-dimer formation in multiplexed assays. The company's product portfolio spans three instrument platforms—the Co-Dx PCR Pro point-of-care system (Bluetooth-connected to mobile devices, ~30-minute results), the Co-Dx PCR Home at-home platform, and the Co-Dx Box portable 48-well magnetic-induction qPCR cycler—together with the Logix Smart diagnostic kit family covering COVID-19, influenza A/B, RSV, tuberculosis, HPV, Zika, dengue, chikungunya, and Mpox, plus the Vector Smart line for mosquito-borne pathogen surveillance. An AI platform branded Primer Ai is layered on top, providing target modeling, reagent optimization, result-calling, and cloud-connected outbreak surveillance capabilities.
The company makes money primarily through one-time sales of consumable test kits and instrument hardware, complemented by royalty and license income from two majority joint ventures—CoSara Diagnostics in India (since 2017, ISO 13485 certified, CDSCO licensed) and CoMira Diagnostics in Saudi Arabia/MENA (formed October 2025, with a 14,400 sq ft manufacturing facility secured in Sudair Industrial City in mid-2026)—and by non-dilutive grant funding of approximately $11.2M from the NIH RADx Tech program and the Bill & Melinda Gates Foundation. Go-to-market combines B2B enterprise sales to clinical laboratories and healthcare facilities, exclusive regional distributor relationships (notably Mexico, which has generated over $18M since 2020), and emerging direct-to-consumer channels for at-home testing through the company's website. Cumulative revenue since 2020 exceeds $200M with 35M+ tests distributed across 50+ countries, though annual revenue has fallen sharply from a 2021 COVID peak of roughly $98M to a sub-$1M run rate in 2025-2026 as COVID demand normalized and the company pivots toward point-of-care and at-home infectious disease testing.
Co-Diagnostics firmographics
Firmographics- Name
- Co-Diagnostics
- Legal name
- Co-Diagnostics, Inc.
- Website
- https://codiagnostics.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Co-Diagnostics (NASDAQ: CODX) is a Salt Lake City-based molecular diagnostics company that develops proprietary Co-Primers-based real-time PCR instruments (Co-Dx PCR Pro, PCR Home, and Co-Dx Box) and multiplex test kits for infectious diseases, serving clinical laboratories, healthcare facilities, governments, and at-home consumers across 50+ countries via direct sales, joint ventures, and distributors.
- Ownership category
- akta.pro rank
Co-Diagnostics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Co-Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Co-Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Product Sales - Test Kits: Sale of molecular diagnostic test kits for infectious diseases including COVID-19, influenza, and other pathogens. One-time purchase model for consumable test kits used with proprietary PCR platforms.
- Instrument Sales: Sale and distribution of Co-Dx PCR Pro platform and Co-Dx Box qPCR cycler instruments to clinical laboratories and healthcare facilities.
- Grant Funding: Non-dilutive funding from NIH RADx Tech program and Bill & Melinda Gates Foundation for development of diagnostic technologies targeting underserved markets and infectious diseases.
- Royalty Income from Joint Ventures: Ongoing royalty revenue from CoSara Diagnostics (India) and CoMira Diagnostics (Saudi Arabia) joint ventures that manufacture and distribute Co-Diagnostics products locally.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Quote-based enterprise pricing |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
Co-Diagnostics product offering
Product offeringCore offering
Co-Diagnostics designs, develops, manufactures, and distributes proprietary real-time PCR molecular diagnostic platforms and consumable test kits used to detect infectious diseases at the point of care, in clinical laboratories, and at home. Its product portfolio is anchored by the Co-Dx PCR Pro point-of-care instrument, the Co-Dx Box portable qPCR cycler, and the Co-Dx PCR Home consumer platform, supported by Logix Smart, Vector Smart, and research-use-only test kits for pathogens including SARS-CoV-2, influenza A/B, RSV, tuberculosis, HPV, Zika, dengue, chikungunya, and mosquito-borne encephalitis viruses.
Product overview
Co-Diagnostics offers a portfolio of molecular diagnostic products centered on its proprietary Co-Dx PCR platform, consisting of the Co-Dx PCR Pro (point-of-care instrument) and Co-Dx PCR Home (at-home testing) platforms. The portfolio includes two instrument lines (Co-Dx PCR Pro and Co-Dx Box qPCR cycler) and multiple test kits under the Logix Smart brand for infectious disease detection including COVID-19, influenza, tuberculosis, HPV, and vector-borne diseases (Zika, Dengue, Chikungunya, West Nile, and other arboviruses). The company also provides AI-powered diagnostic intelligence through its Primer Ai platform for target identification and outbreak surveillance. Products are available as IVD diagnostic tests (CE-IVD marked) and research use only (RUO) formulations, with the CoSara joint venture manufacturing products in India and CoMira joint venture expanding into the Middle East.
Differentiator
Problem solved
Functional benefit
Brands
- Logix Smart: Product line of IVD diagnostic tests including COVID-19, MTB, ABC (Flu A/B, COVID-19), SARS-CoV-2, ZDC, and Zika tests
- Co-Dx Box
- Co-Dx PCR Pro
- Co-Dx PCR Home
- Vector Smart
- Maverick Blue
- Co-Primers
- Primer Ai
- CoSara
- CoMira
Products and services
- Co-Dx PCR Pro Platform A portable real-time PCR instrument that connects via Bluetooth to smartphones and tablets, providing point-of-care multiplex infectious disease testing with single-use sample cartridges in approximately 30 minutes. Designed for healthcare facilities, businesses, and point-of-care settings.
- Co-Dx Box qPCR Cycler A compact, portable 48-well magnetic induction qPCR cycler with a fixed optical path requiring no calibration, designed for laboratories and vector control operations requiring portable real-time PCR capability with cloud connectivity.
- Primer Ai Platform AI platform comprising multiple proprietary models for diagnostic target identification, reagent chemistry optimization, and result accuracy improvement, with cloud-connected outbreak surveillance capabilities enabling public health authorities to track cases in near real-time.
- Logix Smart COVID-19 Test Kit Real-time RT-PCR test for qualitative detection of SARS-CoV-2 RNA from respiratory specimens, authorized under FDA Emergency Use Authorization and CE-IVD marked for international markets.
- Logix Smart ABC Test Kit Multiplex real-time RT-PCR test for qualitative detection and differentiation of influenza A, influenza B, and SARS-CoV-2 from respiratory specimens.
- Logix Smart MTB Test Kit Real-time PCR test for detection of Mycobacterium tuberculosis complex DNA from respiratory specimens, targeting IS6110 and MPB64 gene markers.
- Logix Smart SARS-CoV-2 (RdRp/E) Test Kit Real-time multiplex RT-PCR test targeting RdRp and E genes of SARS-CoV-2 from respiratory and saliva specimens.
- Logix Smart SARS-CoV-2 Direct Saliva (DS) Test Kit Real-time RT-PCR test using a sample processing technique that eliminates nucleic acid extraction, for qualitative detection of SARS-CoV-2 from minimally processed saliva.
- Logix Smart ZDC Test Kit Multiplex real-time RT-PCR test for differentiation and detection of Zika, dengue (all 4 serotypes), and chikungunya viruses from serum and urine specimens.
- Logix Smart Zika Test Kit Real-time RT-PCR test for detection of Zika virus RNA from serum, plasma, and urine specimens targeting conserved regions of the Zika genome.
- Vector Smart NAM-e Test Kit Real-time multiplex PCR test for detection of West Nile virus, St. Louis encephalitis virus, and eastern equine encephalitis virus from mosquito samples.
- Vector Smart NAM-w Test Kit Real-time multiplex PCR test for detection of West Nile virus, St. Louis encephalitis virus, and western equine encephalitis virus from mosquito samples.
- Vector Smart VZDC Test Kit Real-time multiplex PCR test for detection and differentiation of Zika virus, dengue virus (types 1-4), and chikungunya virus from mosquito samples.
- Maverick Blue Nucleic Acid Stain Double-stranded DNA binding dye for real-time PCR and melting applications with blue laser excitation, intended for research use only.
- Co-Dx PCR Flu A/B, COVID-19, RSV Test Kit Multiplex point-of-care PCR test for simultaneous detection and differentiation of influenza A, influenza B, COVID-19, and RSV from nasal swab specimens in under 40 minutes, designed for use with the Co-Dx PCR Pro platform.
- Co-Dx PCR HPV Test Kit 8-type multiplex PCR test differentiating high-risk HPV types 16, 18, and 45, with group detection for types 31, 33, 35, 52, 58. Designed for use with the Co-Dx PCR Pro platform. Currently in development.
- Co-Dx PCR COVID-19 Test Kit Automated rapid RT-PCR test for qualitative detection of SARS-CoV-2 from anterior nasal swab specimens in approximately 30 minutes, for use with the Co-Dx PCR Pro platform.
- Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test Kit Point-of-care PCR test for detection of Mycobacteria tuberculosis from sputum and tongue swab samples, designed for use with the Co-Dx PCR Pro platform in under 40 minutes.
- Co-Dx PCR Home Testing Platform At-home PCR testing platform enabling individuals to perform gold-standard real-time PCR diagnostics from home with results delivered to a smartphone app in approximately 30 minutes.
- Co-Dx Sample Preparation Instrument Proprietary low-cost, user-friendly sample preparation instrument for point-of-care TB testing, designed for decentralized PCR testing in resource-limited settings including sputum and tongue swab samples.
Quantifiable outcome
- Over 35 million tests distributed globally since 2020
- +3 more outcomes
Companies that use Co-Diagnostics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Co-Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability6 records
Feature5 records
Co-Diagnostics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- CoSara Diagnostics Pvt. Ltd.coreJoint venture with Synbiotics Limited/Ambalal Sarabhai Enterprises established in 2017 for manufacturing and distribution of Co-Diagnostics products in India and South Asia. Located in Vadodara, Gujarat, India. Represents key market access strategy for $13B South Asia market opportunity.
- CoMira DiagnosticscoreJoint venture with Arabian Eagle Manufacturing for manufacturing and distribution in Saudi Arabia and MENA region. Facility located in Sudair Industrial City, Saudi Arabia. Strategic partnership for Middle East market expansion.
- Mexico DistributorcoreExclusive distribution partnership for Mexico market. Generated over $18M in revenue since 2020, representing significant international commercial success outside JV structure.
Scale indicators10 records
Recent moves9 records
Expansion highlights6 records
Co-Diagnostics competitors and assessment
Company assessmentBroad incumbents
- Qiagen: Qiagen supplies sample-prep and PCR reagents (QIAcube, QIAstat-Dx) used across molecular diagnostics workflows. It overlaps with Co-Dx on the reagent side of the molecular testing stack and on syndromic panel-based POC testing (QIAstat-Dx Respiratory Panel).
- Hologic: Hologic's Panther system is a high-throughput, fully automated molecular diagnostics platform serving clinical labs. It overlaps with Co-Dx Logix Smart on respiratory and STI menus and brings substantially more scale and installed base.
- Roche Diagnostics: Roche's cobas Liat system is the most-established rapid POC PCR platform for influenza, RSV, and Strep A. Roche also competes with Co-Dx on TB testing (cobas MTB) and HPV (cobas HPV), and now owns the GenMark ePlex syndromic PCR franchise — making it a broad incumbent peer.
- Abbott (Diagnostics): Abbott's molecular diagnostics portfolio (m2000, ID NOW, Alinity m) plus its dominant BinaxNOW antigen franchise compete across both central-lab and POC testing. Comparable on respiratory pathogen detection and at-home testing adjacencies, though Abbott operates across a much broader diagnostics portfolio.
- QuidelOrtho: QuidelOrtho's Sofia and Savanna platforms span rapid antigen, immunoassay, and molecular diagnostics (Savanna is a multiplex PCR system). Comparable on the rapid infectious-disease testing menu and on the POC deployment model that Co-Dx targets.
Emerging players
- Binx Health: Binx Health offers the io molecular platform, a rapid PCR system targeted at point-of-care STI testing (chlamydia/gonorrhea). Comparable on the decentralized PCR instrument footprint and the consumer/clinic workflow, though Binx is focused on sexual health rather than respiratory disease.
- Visby Medical: Visby Medical produces single-use, rapid PCR devices for STI and infectious disease testing without the need for separate instrumentation. Comparable to Co-Dx PCR Pro on the miniaturized, instrument-free POC PCR dimension, though Visby is more focused on the women's health / STI segment.
Direct peers
- bioMérieux (BioFire Diagnostics): BioFire's FilmArray syndromic panels are the closest direct competitor to Co-Dx's multiplex PCR strategy. Three Co-Diagnostics executives (President Richard Abbott, COO David Nielsen, CTO Christopher Thurston) are BioFire alumni, and the technology philosophy — sample-to-answer multiplex PCR — is highly aligned.
- Cepheid (Danaher): Cepheid's GeneXpert system is the gold standard for point-of-care real-time PCR across infectious diseases including TB, HPV, and respiratory pathogens. Directly comparable to Co-Dx PCR Pro on platform architecture, multiplex capability, and target customer (clinical labs and decentralized testing sites).
- Cue Health: Cue Health developed the Cue Reader, a connected at-home molecular diagnostic platform for respiratory and sexual health testing — directly analogous to Co-Dx PCR Home. Both companies target consumer/employer channels with cloud-connected PCR cartridges, though Cue's recent operating struggles underscore the category's execution risk.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Co-Diagnostics social profiles
Digital presenceCo-Diagnostics compliance and trust
Trust signalCompliance9 records
Co-Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Co-Diagnostics leadership team
Management profileNumber of profiles
Profiles9 records
Co-Diagnostics subsidiaries and ownership
Company hierarchySubsidiaries4 records
Co-Diagnostics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Co-Diagnostics M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Co-Diagnostics
What does Co-Diagnostics do?
Co-Diagnostics designs, develops, manufactures, and distributes proprietary real-time PCR molecular diagnostic platforms and consumable test kits used to detect infectious diseases at the point of care, in clinical laboratories, and at home. Its product portfolio is anchored by the Co-Dx PCR Pro point-of-care instrument, the Co-Dx Box portable qPCR cycler, and the Co-Dx PCR Home consumer platform, supported by Logix Smart, Vector Smart, and research-use-only test kits for pathogens including SARS-CoV-2, influenza A/B, RSV, tuberculosis, HPV, Zika, dengue, chikungunya, and mosquito-borne encephalitis viruses.
Is Co-Diagnostics a public or private company?
Co-Diagnostics is a public company. It is classified as public and is currently operating.
When was Co-Diagnostics founded?
Co-Diagnostics was founded in 2013. It employs 101 to 250 people.
Where is Co-Diagnostics based?
Co-Diagnostics is headquartered in Salt Lake City, United States, in the North America region.
How does Co-Diagnostics make money?
Four revenue lines are on record. Product Sales - Test Kits are the primary driver. The others are instrument Sales, grant Funding and royalty Income from Joint Ventures.
Who are Co-Diagnostics's main competitors?
Broad incumbents on record are Qiagen, Hologic, Roche Diagnostics, Abbott (Diagnostics) and QuidelOrtho. Emerging players are Binx Health and Visby Medical. Direct peers are bioMérieux (BioFire Diagnostics), Cepheid (Danaher) and Cue Health.
Does Co-Diagnostics have an API?
No public API is recorded for Co-Diagnostics.
What industry is Co-Diagnostics in?
Co-Diagnostics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.